NeuropharmacologyJanuary 2017Melanie Clarke, Sara Razmjou, Natalie Prowse et al.
Considerable recent attention has focused on the rapid antidepressant effects observed in treatment resistant patients produced by the NMDA receptor antagonist, ketamine. Surprisingly, the effects of ketamine in the context of stressor exposure, as well as the consequences of its chronic use are unclear. Thus, we assessed the impact of acute and repeated ketamine treatment together with acute...
Approximately one-third of patients with major depressive disorders (MDDs) are resistant to current treatment methods, and the majority of cases relapse at some point during therapy. This has resulted in novel treatments being adopted, including subanesthetic doses of ketamine, which affects aberrant neuroplastic circuits, glutamatergic signaling, and the production of brain-derived...
Objective: To evaluate the potential synergistic effect of ketmaine and magnesium treatment on prefrontal cortex (PFC) and hippocampal BDNF expression and depressive-like behavior in mice model. Background: Ketamine, an NMDA receptor antagonist with neuroplastic effect on up-regulation of BDNF, has been investigated significantly as a fast acting antidepressant particularly in treatment...
Depression is a common chronic psychiatric disorder that is also often co-morbid with numerous neurological and immune diseases. Accumulating evidence indicates that disturbances of neuroplasticity occur with depression, including reductions of hippocampal neurogenesis and cortical synaptogenesis. Improper trophic support stemming from stressor-induced reductions of growth factors, most notably...